永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 04-15 16:08:06

3.670

+0.090

+2.51%

最高3.700	最低3.550	成交量35.89万
今开3.580	昨收3.580	日振幅4.19%
总市值22.68亿	流通市值22.68亿	总股本6.18亿
成交额129.25万	换手率0.06%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.67,"timestamp":1776240486861,"preClose":3.58,"halted":0,"volume":358882,"delay":0,"changeRate":0.025139664804469233,"floatShares":618000000,"shares":618000000,"eps":-0.4829440526563234,"marketStatus":"已收盘","change":0.09,"latestTime":"04-15 16:08:06","open":3.58,"high":3.7,"low":3.55,"amount":1292463,"amplitude":0.041899,"askPrice":3.68,"askSize":11000,"bidPrice":3.67,"bidSize":13000,"shortable":0,"etf":0,"ttmEps":-0.4760448519040902,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.58,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":0.26748,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/","defaultTab":"news","newsList":[{"id":"2627409734","title":"4月15日博瑞医药（688166）涨停分析：创新药进展、集采落地、政策加码驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627409734","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627409734?lang=zh_cn&edition=full","pubTime":"2026-04-15 15:33","pubTimestamp":1776238408,"startTime":"0","endTime":"0","summary":"证券之星消息，博瑞医药4月15日涨停收盘，收盘价57.66元。该股于11点22分涨停，1次打开涨停，截止收盘封单资金为1.21亿元，占其流通市值0.49%。今日博瑞医药涨停的可能因素有：BGM0504注射液国内III期临床完成入组、美国II期会议顺利结束，与华润三九达成商业化合作；地诺孕素片及布地奈德混悬液获批，4个产品拟中标国家集采接续采购；工信部吹风加快打造“创新医药”，明确支持创新药加速上市与合理定价，政策催化显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500022614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","06978","BK0239","688166","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价，创新药爆发！涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"fut","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["600267","000788","159992","BK0239","BK0122","BK0132","BK0028","BK0197","600488","02162","BK0250","000919","BK0012","002589","BK0097","BK0077","301408","BK1574","BK1161","600572","BK0185","06978","BK0060","BK0096","BK0102","BK1583","002038","06990","BK0070","LU0196878994.USD","BK0209","BK0188","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405527","title":"创新药出海爆发！一季度BD交易额破600亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405527","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405527?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:26","pubTimestamp":1776234405,"startTime":"0","endTime":"0","summary":"今日，医药板块持续走强，恒生生物科技指数（HSBIO.HI）盘中涨幅3.21%。相关ETF方面，港股通生物科技ETF（159102）场内价格现涨2.91%。截至上个交易日数据，该基金15日累计涨幅8.26%，动能强劲。成分股方面，三生制药涨超6%，康方生物涨超4%，信达生物涨超3%，映恩生物-B、科伦博泰生物-B、晶态控股等涨幅靠前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705806464.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705806464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540852","title":"港股创新药板块午后持续走高，荣昌生物涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540852","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540852?lang=zh_cn&edition=full","pubTime":"2026-04-15 13:10","pubTimestamp":1776229832,"startTime":"0","endTime":"0","summary":"4月15日，港股创新药板块午后持续走高，荣昌生物涨近10%，君实生物涨超5%，诺诚健华、信达生物、复星医药跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705735216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705735216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2148510915.USD","BK0239","159992","LU1969619763.USD","688331","LU2328871848.SGD","BK1583","06978","LU2488822045.USD","LU1064130708.USD","09995","BK4588","VXUS","BK4585","BK1161","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627994470","title":"三大指数齐涨 创新药领涨 石油股走低丨港股午评","url":"https://stock-news.laohu8.com/highlight/detail?id=2627994470","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627994470?lang=zh_cn&edition=full","pubTime":"2026-04-15 12:40","pubTimestamp":1776228000,"startTime":"0","endTime":"0","summary":"港股早盘三大指数齐涨，恒指涨0.76%，国指涨0.87%，恒生科技指数涨1.88%。创新药概念领涨，轩竹生物-B涨超12%，劲方医药-B、荣昌生物等跟涨。消息面上，诺和诺德宣布与OpenAI建立战略合作伙伴关系，此次合作将运用先进的人工智能能力分析复杂数据集，筛选具有潜力的候选药物，并缩短从基础研究到惠及患者所需的时间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705709370.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705709370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OILU","DBE","DRLL","IEO","BK4570","BK1574","XOP","OIH","OILK","VXUS","DRIP","PXJ","VDE","USE","06978","ERX","BK4585","DIG","159992","BK4588","DBC","USOI","IXC","XLE","OILT","GUSH","BK1161","USL","BNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627474051","title":"工信部：合力支持创新药早日生产、早日上市、早日进医院","url":"https://stock-news.laohu8.com/highlight/detail?id=2627474051","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627474051?lang=zh_cn&edition=full","pubTime":"2026-04-15 11:24","pubTimestamp":1776223460,"startTime":"0","endTime":"0","summary":"加快打造“创新医药”","market":"hk","thumbnail":"https://img3.gelonghui.com/29897-ff22031f-3416-42cd-98e0-32887c7aa576.jpg?guru_height=3264&guru_width=5824&guru_size=1378769","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/29897-ff22031f-3416-42cd-98e0-32887c7aa576.jpg?guru_height=3264&guru_width=5824&guru_size=1378769"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4417070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1161","06978","IPOS","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476418","title":"A股盘前播报 | 特朗普最新发声！纳指十连涨、油价下挫 国办重磅！创新药迎政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627476418?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:25","pubTimestamp":1776212752,"startTime":"0","endTime":"0","summary":"盘前要闻1、特朗普称未来两天内再会谈！纳指十连涨科技牛股新高，油价大幅下挫类型：市场情绪影响：正面美国总统特朗普周二表示，新一轮美伊会谈“可能未来两天内”在巴基斯坦举行，并称美国对伊朗战争已经结束。纳指涨1.96%，连续十日上涨。存储牛股美光科技大涨9.17%刷新收盘新高。这是央行连续两个月缩量续作6个月期买断式逆回购。消息公布后，Globalstar股价早盘涨逾9%，亚马逊股价上涨逾2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TQQQ","BNO","OILU","DIG","DBO","NVIW.SI","VDE","159982","USOI","399300","QQQM","DBC","159659","ERX","TQQY","PSQ",".IXIC","06978","NDX","OIH","JEPQ","USE","USL","OILT","UGA","QQQI","TECL","03086","DBE","OILK","NQmain","159992","IEO","ONEQ","SQQQ","FTEC","QQQE","MNQmain","DRIP","IXC","PXJ","BWET","QQQ","QQQY","QDTE","DUG","DRLL","QQQA","QID","GUSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245420","title":"港股概念追踪 | 创新药板块迎政策东风 国办发文健全药品价格形成机制（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245420","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627245420?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:16","pubTimestamp":1776208598,"startTime":"0","endTime":"0","summary":"意见从4个方面提出14条举措，包括完善重点环节药品价格政策、推动相关主体发挥药品价格发现作用、引导关键领域药品价格保持合理水平、加强药品价格治理。具体举措包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、健全药品集中带量采购价格形成机制、完善药品挂网价格管理。《意见》发布后，市场普遍认为新政将为医药产业特别是创新药带来发展新契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","VXUS","LU1242518857.USD","02269","BK1589","BK1610","LU0979878070.USD","LU0348825331.USD","LU0417516902.SGD","LU0819121731.USD","LU2242644610.SGD","LU0516422366.SGD","BK1583","LU0588546209.SGD","BK1141","LU0052750758.USD","LU0181495838.USD","LU0348735423.USD","LU1046422090.SGD","IE00B0JY6N72.USD","LU0326950275.SGD","LU0359202008.SGD","LU2045819591.USD","BK1574","06978","LU1242518931.SGD","BK1161","LU0307460666.USD","LU0051755006.USD","LU0516422952.EUR","SG9999002463.SGD","LU0039217434.USD","LU0320764599.SGD","LU0823426308.USD","06127","LU0456827905.SGD","LU2039709279.SGD","LU0708995583.HKD","LU0327786744.USD","LU0516422440.USD","LU0359201612.USD","LU0043850808.USD","LU0856984785.SGD","02315","LU0572944931.SGD","159992","BK4585","02359","LU0516423091.SGD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416823","title":"大华继显：降阿里健康(00241)目标价至6港元 下调盈测反映创新药及AI投资增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416823","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627416823?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:13","pubTimestamp":1776154437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大华继显发布研报称，阿里健康(00241)重申其2026财年营收增长目标为年增10%至15%，同时将调整后净利增长目标从20%至30%下调至10%至20%，原因是公司加大了对创新药物和AI投资。该行将集团2026财年调整后净利润成长预期从25%下调至15%，同时维持2026-2028财年营收和调整后净利润复合年均增长率分别为13%和24%，主要得益于创新药物的强劲势头、阿里巴巴协同效应的深化及AI应用的不断扩大。维持“买入”评级，但降目标价由7.8港元至6港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","EWH","CHAT","159992","AIPO","00241","06978","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627494406","title":"“明星”抗癌药中国“七连发”：跨国药企加速重塑在华商业模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2627494406","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627494406?lang=zh_cn&edition=full","pubTime":"2026-04-14 13:17","pubTimestamp":1776143820,"startTime":"0","endTime":"0","summary":"近日，由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破：其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”，中国患者成为全球最早受益于这一创新疗法的群体。这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来，这款被称为“大魔王”的抗体偶联药物（ADC）在中国接连拿下七项适应症，覆盖乳腺癌、肺癌、胃癌等多个领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704221860.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704221860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1574","BK4080","BK1161","BK4231","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627983499","title":"港股异动 | 绿叶制药(02186)午前涨近3% 近日自研创新药LY03020中国Ⅱ期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627983499","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627983499?lang=zh_cn&edition=full","pubTime":"2026-04-14 11:54","pubTimestamp":1776138882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药午前涨近3%，截至发稿，涨2.52%，报2.85港元，成交额5323.6万港元。消息面上，近日，绿叶制药发布公告，本集团自主研发的创新药LY03020的中国Ⅱ期临床已完成首例患者入组。此前，LY03020亦已在美国获准开展临床试验，是本集团在中国和海外同步开发的又一款中枢神经系统治疗领域的创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4585","06978","BK1191","BK1161","02186","BK4588","VXUS","BK1574","159992","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245839","title":"创新药赛道低位整理，港股通创新药ETF易方达（159316）今日净申购达3400万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627245839?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:05","pubTimestamp":1776081908,"startTime":"0","endTime":"0","summary":"4月13日，创新药赛道低位整理，指数层面，恒生港股通创新药指数下跌1.2%，中证创新药产业指数下跌0.6%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)全天获3400万份净申购。中国银河证券指出，当前创新药板块的调整更多是受技术性回调与情绪因素所致，估值底部已基本明确。2026年，创新药板块或呈现明显的结构性分化，具备核心管线临床数据兑现能力和大额商务拓展交易支撑的龙头企业将更具确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041300029668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","159992","BK1161","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627338194","title":"申万宏源：26年一季报披露期临近 关注创新药、CXO及上游","url":"https://stock-news.laohu8.com/highlight/detail?id=2627338194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627338194?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:10","pubTimestamp":1776067851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，截止至4月12日共有8家医药上市公司发布2026Q1业绩预告，其中6家利润同比增长，2家同比下滑。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期，重点推荐。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期其中，CXO板块的业绩增长主要得益于全球创新药行业景气度持续向好，行业新签订单呈现良好增长，国内外医药投融资景气度持续上行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","000166","06806","BK1574","BK0188","CXO","BK0028","BK1564","BK1147","BK0183","159992","BK0012","BK0276","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627460483","title":"创新药概念震荡回升 君实生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627460483","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627460483?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:47","pubTimestamp":1776048478,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，创新药概念盘中震荡回升，君实生物涨超10%，通化金马一度逼近涨停，常山药业、圣诺生物、荣昌生物、新诺威、三生国健涨幅靠前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702633963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702633963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","01877","688180","06978","BK1515","BK1574","159992","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710069","title":"7.45亿美元！创新药龙头再获天价大单！","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627710069?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:19","pubTimestamp":1776043140,"startTime":"0","endTime":"0","summary":"4月12日，海思科宣布与美国公司AbbVie Group Holdings Ltd．签订Nav1.8抑制剂授权协议，将获得3000万美元首付款及最高7.15亿美元的里程碑付款，AbbVie还将支持相关开发费用。公司旗下选择性Nav1.8阻断剂HSK55718和HSK51155通过抑制痛觉神经异常放电，意在开发为疼痛治疗药物。　　生物医药领域的创新药对外授权交易持续活跃，近期海思科与艾伯维就Nav1.8抑制剂达成的授权协议进一步印证了这一趋势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-13/doc-inhuihze5709901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627104498","title":"创新药龙头再获天价大单，一季度净利约去年全年2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2627104498","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627104498?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:47","pubTimestamp":1776037620,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　4月12日晚间，海思科连发三份重磅公告，交出了一份极具“反转色彩”的成绩单。　　据海思科2026年第一季度业绩预告，公司预计当期归属于上市公司股东的净利润为4.77亿元至5.57亿元，同比增长923.34%至1094.97%；扣除非经常性损益后的净利润为4.49亿元至5.29亿元，同比增长791.94%至950.86%。21快讯记者注意到，海思科仅一季度净利润，就已接近2025年全年2.60亿元净利润的约两倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-13/doc-inhuiath5799064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626617252","title":"瞄准创新药板块！基金经理，新打法曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2626617252","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626617252?lang=zh_cn&edition=full","pubTime":"2026-04-12 17:43","pubTimestamp":1775986980,"startTime":"0","endTime":"0","summary":"伴随各类事件催化进入密集兑现周期，不少基金经理开始切换布局创新药对冲组合风险。　　为对冲持仓波动、稳住组合收益，在老龄化趋势中迎来景气度利好，兼具刚需弹性与防御属性的创新药赛道，正靠着密集的事件驱动逻辑，逐渐成为基金经理调仓避险的重要选择。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-12/doc-inhufuye5534581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626171216","title":"海思科最新公告：一季度净利同比预增923%-1095%创新药销售保持良好增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626171216","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626171216?lang=zh_cn&edition=full","pubTime":"2026-04-12 15:40","pubTimestamp":1775979644,"startTime":"0","endTime":"0","summary":"海思科公告称，预计2026年第一季度归属于上市公司股东的净利润为4.77亿元-5.57亿元，比上年同期增长923.34%-1094.97%。公司积极拓展市场，创新药销售持续保持良好增长。因此，在研发费用保持较高增长的情况下，公司归属于上市公司股东的净利润及扣除非经常性损益后的净利润仍实现了较高的增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200002766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002653","BK1161","BK0239","159992","BK1574","BK0033","06978","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626147650","title":"和讯信息冯禄顺：创新药接下来怎么走","url":"https://stock-news.laohu8.com/highlight/detail?id=2626147650","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626147650?lang=zh_cn&edition=full","pubTime":"2026-04-11 13:28","pubTimestamp":1775885283,"startTime":"0","endTime":"0","summary":"4月10日，咱们解读一下来创新药指数。创新药方向迎来缩量反弹，反弹的核心原因的是，当日高位科技板块开始调整，低位的创新药板块随之迎来修复行情。再看港股创新药，今日港股正常开盘，其走势与A股创新药有所呼应。港股创新药的操作逻辑与A股类似：回踩5周线、5天线时可低吸进场，反弹后及时止盈；一旦跌破5天线，大概率会回踩5周线，毕竟当前股价与5周线存在一定距离。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260411/32138321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118371","title":"康芝药业：公司目前暂无正在开发中的创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626118371?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:52","pubTimestamp":1775825541,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价从高点回落近50%，公司是否有正在开发中的创新药？康芝药业回复：您好！公司目前暂无正在开发中的创新药。公司在研项目主要聚焦于儿童用药领域，涵盖改良型新药、首仿药以及中药二次开发等方向。敬请广大投资者谨慎决策，注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000039000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","06978","159992","BK1574","BK0070","BK1161","300086","BK0048","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.3162},{"period":"1month","weight":0.4039},{"period":"3month","weight":0.2832},{"period":"6month","weight":-0.035},{"period":"1year","weight":-0.1204},{"period":"ytd","weight":0.2218}],"compareEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.208},{"period":"ytd","weight":0.0094}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.009692},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}